Zepbound® — The First Dual-Action GLP-1/GIP for Weight Management

Tirzepatide (the active ingredient in Zepbound®) and semaglutide (the active ingredient in Ozempic® and Wegovy®) are fundamentally different molecules, despite belonging to the same broader class of incretin-based therapies. Understanding this difference matters because it affects how the medication works in your body and why some patients respond better to one than the other.

Semaglutide is a GLP-1 receptor agonist — it activates one receptor pathway. Tirzepatide is a dual GLP-1/GIP receptor agonist — it activates two receptor pathways simultaneously. This is not a marketing distinction; it is a molecular and pharmacological difference.

GLP-1 and GIP are both incretin hormones, meaning they are released by your gut after eating and play roles in regulating blood sugar, appetite, and energy metabolism. But they act through different receptors and influence different downstream effects. GLP-1 is well understood as an appetite suppressant and gastric-emptying regulator. GIP’s role is more complex and still being studied, but evidence suggests it enhances the metabolic effects of GLP-1 signaling, influences fat tissue metabolism, and may contribute to improved energy balance through mechanisms that GLP-1 alone does not fully address.

The clinical result of this dual action has been substantial. In the SURMOUNT-1 trial, tirzepatide at its highest dose (15 mg) produced an average weight loss of 22.5% over 72 weeks — compared to approximately 15% for semaglutide 2.4 mg in the STEP 1 trial over 68 weeks. While cross-trial comparisons should be interpreted with caution (different patient populations, different designs), these results suggest a meaningful efficacy advantage for the dual-receptor approach.

The SURMOUNT trial program is the clinical foundation behind Zepbound®’s FDA approval for weight management. It is one of the largest and most comprehensive trial programs ever conducted for an anti-obesity medication, enrolling thousands of adults across multiple countries.

SURMOUNT-1 studied tirzepatide in adults with obesity or overweight (without type 2 diabetes) who also had at least one weight-related condition. Over 72 weeks, patients receiving tirzepatide achieved dose-dependent weight loss: an average of 15% at the 5 mg dose, 19.5% at the 10 mg dose, and 22.5% at the 15 mg dose. The placebo group achieved approximately 3.1%. To put the 15 mg result in concrete terms: a 250-pound patient would lose approximately 56 pounds on average.

More than one-third of patients receiving the highest dose lost 25% or more of their body weight — a threshold previously achievable primarily through bariatric surgery, not medication.

SURMOUNT-2 studied tirzepatide in patients with both obesity and type 2 diabetes, where weight loss outcomes are typically more modest. Even in this harder-to-treat population, tirzepatide produced average weight loss of 12.8% at the 10 mg dose and 14.7% at the 15 mg dose.

SURMOUNT-3 and SURMOUNT-4 examined tirzepatide in combination with intensive lifestyle intervention and as a maintenance therapy after initial weight loss, respectively, with consistently strong results.

These trials established tirzepatide as the most effective pharmacological weight management agent studied to date in terms of average percentage of body weight lost.

Zepbound® uses a gradual dose-escalation schedule designed to minimize gastrointestinal side effects and allow your body to adapt to the dual GLP-1/GIP mechanism.

Weeks 1-4: 2.5 mg once weekly (initiation dose — primarily for tolerability). Weeks 5-8: 5 mg once weekly. Weeks 9-12: 7.5 mg once weekly. Weeks 13-16: 10 mg once weekly. Weeks 17-20: 12.5 mg once weekly. Week 21 onward: 15 mg once weekly (maximum maintenance dose).

Not every patient will escalate to 15 mg. Your provider determines your optimal maintenance dose based on your weight loss response, side effect tolerance, and clinical goals. Some patients achieve excellent results at 10 mg or 12.5 mg and remain at that level. Others benefit from reaching the full 15 mg dose. If side effects are difficult to manage at any step, your provider can extend that dose level for additional weeks before increasing.

Each dose level uses a different pen strength — you will receive new pens at each escalation step. The entire escalation from 2.5 mg to 15 mg takes approximately 20 weeks under the standard schedule.

Zepbound® comes in a single-dose, pre-filled injection pen. Unlike multi-dose pens (such as Ozempic®), each Zepbound® pen contains exactly one dose and is disposed of after a single use. There is no dial to set, no dose to select, and no cartridge to load.

To use the pen: remove the cap to reveal the needle, choose an injection site (stomach, thigh, or back of upper arm), place the pen flat against your skin, press and hold the injection button until you hear two clicks — the first indicates the injection has started, the second indicates it is complete. Keep the pen pressed against your skin for the full duration (approximately 5-10 seconds). Then remove and dispose of the pen in a sharps container.

The single-dose design eliminates dosing errors and simplifies the injection process. Most patients find it slightly easier to use than multi-dose pen systems because there are fewer steps and no opportunity to dial an incorrect dose.

Rotate injection sites each week. Store unused pens in the refrigerator (36°F to 46°F). You may keep a pen at room temperature (up to 86°F) for up to 21 days if needed. Do not freeze.

Zepbound® and Mounjaro® contain the identical active ingredient — tirzepatide — manufactured by the same company (Eli Lilly). They are the same molecule in the same pen format. The difference is entirely regulatory.

Mounjaro® is FDA-approved for the management of type 2 diabetes. When it is prescribed for weight management, that is off-label use.

Zepbound® is FDA-approved specifically for chronic weight management in adults with obesity or overweight. When your provider prescribes Zepbound®, they are prescribing it for its intended, on-label purpose.

From a clinical standpoint — the molecule, the dose, the mechanism, the side effects, and the expected outcomes — Zepbound® and Mounjaro® are the same. Your provider will prescribe whichever brand is most appropriate based on your clinical needs.

Yes, and this is a relatively common clinical scenario. Patients may switch from a semaglutide-based medication (Ozempic® or Wegovy®) to Zepbound® for several reasons: they have plateaued on semaglutide and are looking for the additional efficacy that dual GLP-1/GIP activation may provide, or they are experiencing side effects on semaglutide that they hope may differ with tirzepatide.

Because tirzepatide and semaglutide are different molecules, switching is not a simple dose-for-dose conversion. Your provider will typically restart you at a lower dose of tirzepatide (2.5 mg) and escalate gradually, even if you were at a high dose of semaglutide. This is important because the dual GLP-1/GIP mechanism means your body needs time to adapt to the new receptor activity profile, even if you are accustomed to GLP-1 stimulation from semaglutide.

Your provider will manage the transition, including the timing of your last semaglutide dose relative to your first tirzepatide dose, to ensure safety and continuity of care.

Hair thinning or hair loss (telogen effluvium) has been reported by some patients taking Zepbound®, and it is a topic that generates significant patient concern. It is important to understand the context.

Hair loss in this situation is most likely associated with rapid weight loss itself — not with the medication directly. When the body undergoes significant caloric deficit and rapid weight change, it can redirect resources away from non-essential functions like hair growth, causing a temporary increase in hair shedding. This phenomenon is well-documented after bariatric surgery, crash diets, and other rapid-weight-loss scenarios — not just GLP-1 medication use.

In the SURMOUNT trials, hair loss was reported more frequently in tirzepatide groups than placebo, but the rate was relatively low and correlated with the degree of weight loss. Most cases were temporary and resolved as weight stabilized.

If hair thinning concerns you, discuss it with your provider. Strategies may include ensuring adequate protein intake, maintaining appropriate caloric levels (rapid extreme restriction can worsen hair shedding), and in some cases, supplementation. Your provider can also adjust the pace of your dose escalation to moderate the rate of weight loss if appropriate.